Department of Gastroenterology, Imam Khomeini Medical Sciences, Urmia University of Medical Sciences, Urmia 5714783734, Iran.
Pharmaceutical Engineering Department, Faculty of Chemical Engineering, University of Tehran, Tehran 1417414418, Iran.
Int Immunopharmacol. 2021 Mar;92:107355. doi: 10.1016/j.intimp.2020.107355. Epub 2021 Jan 8.
Colorectal cancer (CRC) is one of the most common causes of cancer-related deaths worldwide. The role of microRNAs (miRNAs/miRs) as small (19-25 nucleotides in length) non-coding RNA molecules that modify gene expression has been shown in several types of cancer. 5-Fluorouracil (5-FU) and oxaliplatin (Ox) are two common chemotherapeutic agents used to treat cancer. The present study aimed to evaluate the expression levels of miR-193a-5p in CRC, and its effect on the C-X-C Motif Chemokine Receptor 4 (CXCR4) target gene alone and in combination with chemotherapeutic drugs, to determine its possible role in chemoresistance. CRC tissues and adjacent non-cancerous tissue were obtained from 67 patients who had undergone surgery to determine the expression levels of miR-193a-5p and CXCR4. Subsequently, qPCR and Western blotting were performed to determine the effect of miR-193a-5p and chemotherapy drugs on CXCR4. َAlso, MTT assay, and flow cytometry was performed to determine their role in cell viability and apoptosis. Besides, the relationship between miR-193a-5p and CXCR4 with patients' clinical features was investigated. The results of the present study showed that miR-193a-5p was significantly downregulated, whereas CXCR4 was significantly upregulated in tumor tissues obtained from patients with CRC compared with the adjacent non-tumor healthy controls. In addition, the upregulation of miR-193-5p reduced the expression levels of CXCR4, particularly in combination with 5-FU and OX. Besides, using rescue experiments, the present study showed that miR-193a-5p replacement was able to suppress CXCR4-induced CRC cell proliferation by directly targeting CXCR4. Furthermore, there was a significant association between miR-193a-5p and CXCR4 with certain clinicopathological characteristics, particularly with metastasis-related features. These results suggest that miR-193a-5p serves a tumor-suppressive function in CRC and can directly target CXCR4 and decrease its mRNA and protein expression levels. Additionally, miR-193a-5p in combination with 5-FU and Ox potentiated reducing CXR4 expression, which may reveal its contribution to tumor chemoresistance. In conclusion, miR-193-5p may be applicable as a prognostic and diagnostic marker, and also serve as a therapeutic factor by reducing CXCR4 in combination with chemotherapeutic drugs.
结直肠癌(CRC)是全球癌症相关死亡的最常见原因之一。微小 RNA(miRNAs/miRs)作为调节基因表达的小(19-25 个核苷酸长)非编码 RNA 分子,在多种类型的癌症中已得到证实。5-氟尿嘧啶(5-FU)和奥沙利铂(Ox)是两种常用于治疗癌症的常用化疗药物。本研究旨在评估 miR-193a-5p 在 CRC 中的表达水平,及其单独及与化疗药物联合对 C-X-C 基序趋化因子受体 4(CXCR4)靶基因的影响,以确定其在化疗耐药中的可能作用。从 67 名接受手术的患者中获得 CRC 组织和相邻非癌组织,以确定 miR-193a-5p 和 CXCR4 的表达水平。随后,进行 qPCR 和 Western blot 以确定 miR-193a-5p 和化疗药物对 CXCR4 的影响。此外,进行 MTT 测定和流式细胞术以确定它们在细胞活力和凋亡中的作用。此外,还研究了 miR-193a-5p 与 CXCR4 与患者临床特征之间的关系。本研究结果表明,与相邻非肿瘤健康对照相比,CRC 患者肿瘤组织中 miR-193a-5p 明显下调,而 CXCR4 明显上调。此外,miR-193-5p 的上调降低了 CXCR4 的表达水平,特别是与 5-FU 和 OX 联合使用时。此外,通过挽救实验,本研究表明 miR-193a-5p 替代能够通过直接靶向 CXCR4 抑制 CXCR4 诱导的 CRC 细胞增殖。此外,miR-193a-5p 与 CXCR4 与某些临床病理特征之间存在显著关联,特别是与转移相关特征。这些结果表明,miR-193a-5p 在 CRC 中发挥肿瘤抑制功能,可直接靶向 CXCR4 并降低其 mRNA 和蛋白表达水平。此外,miR-193a-5p 与 5-FU 和 Ox 联合使用可降低 CXR4 表达,这可能揭示其对肿瘤化疗耐药的贡献。总之,miR-193-5p 可能作为预后和诊断标志物,并且通过与化疗药物联合减少 CXCR4 作为治疗因子。